Related Experiment Video
Updated: Sep 25, 2025
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper
Sarah Bailly1, Guillaume Cartron2, Sridhar Chaganti3
1Département d'Hématologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Abstract:
The ubiquitous, early-stage expression, efficient internalization, limited off-target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti-CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Selection of the most appropriate treatment strategy should be based on individual patient characteristics and the goal of therapy. However, evidence and knowledge about the sequencing of anti-CD19 therapies are limited. Here, we review the current evidence for CD19 as a target in diffuse large B-cell lymphoma and consider approaches to the use of anti-CD19 therapy.
Insights
CD19 is a promising target for treating B-cell non-Hodgkin lymphoma. This review examines current evidence for CD19-targeted therapies and discusses optimal sequencing strategies for diffuse large B-cell lymphoma patients.
Area of Science:
- Oncology
- Immunotherapy
- Hematology
Background:
- CD19 is a highly specific cell surface antigen expressed early in B-cell development.
- Its characteristics make CD19 an attractive target for novel cancer therapies.
- Current anti-CD19 therapies show efficacy in relapsed or refractory B-cell non-Hodgkin lymphoma.
Purpose of the Study:
- To review the evidence for CD19 as a therapeutic target in diffuse large B-cell lymphoma (DLBCL).
- To discuss current approaches and future strategies for utilizing anti-CD19 therapies.
- To address the limited knowledge regarding the optimal sequencing of these treatments.
Main Methods:
- Literature review of current clinical evidence.
- Analysis of CD19 expression patterns and therapeutic implications.
- Discussion of treatment strategies in the context of patient characteristics.
Main Results:
- CD19's properties support its role as a key therapeutic target in B-cell malignancies.
- Anti-CD19 therapies are effective in specific patient populations with relapsed/refractory disease.
- Evidence for optimal sequencing of anti-CD19 therapies remains limited.
Conclusions:
- CD19 targeted therapy represents a significant advancement in treating B-cell lymphomas.
- Personalized treatment selection is crucial for optimizing outcomes.
- Further research is needed to establish evidence-based sequencing guidelines for anti-CD19 therapies in DLBCL.
